Axelia Oncology
Melbourne, AU · 1 known investors
Find your way into Axelia Oncology
Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors. The company focuses on oncology therapeutics through activation of TLR2/6 pathways.
Founders & leadership
DJ
David JacksonFounder (Laboratory research origin)
GM
Grant MchlachlanChief Executive Officer
Investors · 1
In the news
Frequently asked questions
- What does Axelia Oncology do?
- Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors. The company focuses on oncology therapeutics through activation of TLR2/6 pathways.
- Who founded Axelia Oncology?
- Axelia Oncology was founded by David Jackson.
- Who are Axelia Oncology's investors?
- Axelia Oncology's investors include Stoic VC.
- Where is Axelia Oncology headquartered?
- Axelia Oncology is headquartered in Melbourne, AU.